Hyperfine (HYPR) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Hyperfine (NASDAQ: HYPR):

• 11/8/2026 – Hyperfine was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/31/2026 – Hyperfine was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/27/2026 – Hyperfine was given a new $2.00 price target by Loop Capital.
• 10/27/2026 – Hyperfine is now covered by Lucid Cap Mkts. They set a “strong-buy” rating on the stock.
• 10/15/2026 – Hyperfine had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/22/2026 – Hyperfine had its “buy” rating reaffirmed by BTIG Research. They now have a $2.00 price target on the stock.
• 9/14/2026 – Hyperfine had its “buy” rating reaffirmed by BTIG Research. They now have a $2.00 price target on the stock.

Hyperfine Stock Performance

Shares of Hyperfine stock opened at $0.71 on Tuesday. The firm has a market capitalization of $75.30 million, a P/E ratio of -1.87 and a beta of 1.49. The company has a quick ratio of 5.45, a current ratio of 6.15 and a debt-to-equity ratio of 0.36. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $1.11. Hyperfine, Inc. has a 52 week low of $0.67 and a 52 week high of $1.94.

Hyperfine (NASDAQ:HYPR) last released its earnings results on Monday, November 9th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $5.96 million during the quarter, compared to analysts’ expectations of $5.84 million. Hyperfine had a negative net margin of 210.75% and a negative return on equity of 97.88%. Sell-side analysts expect that Hyperfine, Inc. will post -0.34 EPS for the current year.

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside.